ClinicalTrials.gg
CompletedNCT04823130DIFFEREN-STADUpdated Sep 16, 2025Results posted

Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis

A Phase 4 interventional study of Dupilumab (SAR231893) in Dermatitis Atopic, sponsored by Sanofi. Completed at 3 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-16.

Sponsored by Sanofi · Phase 4, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
54
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.

Enrollment
29th of 50
54 · median 75
Started
2021
with 4 others
Phase 4
24 of 50
4 open now
Registered
32nd of 50
by date
Lead sponsor
10 of 50
Sanofi

Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 29th largest by enrollment, is one of 5 that started in 2021, is one of 24 in phase 4, and was the 32nd registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing dupilumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

Primary Objective:

- Assess change in neuronal architecture following long term treatment with dupilumab in skin biopsies from atopic dermatitis (AD) participants with chronic pruritus.

Secondary Objectives:

  • Assess change in neuronal architecture following short term treatment with dupilumab and during follow-up in skin biopsies from AD participants with chronic pruritus.
  • To evaluate the efficacy of dupilumab in AD participants with chronic pruritus.
  • To evaluate the safety of dupilumab in adult participants with moderate-to-severe AD.
Read the detailed description

AD participants: A 20-week Observation Period including 16 weeks of treatment for AD participants and a 4-week follow-up period; Healthy participants: 8 days observation period.

03

Conditions studied

  • Dermatitis Atopic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For AD participants

  • Male or female of greater than or equal to (>=)18 years of age inclusive, at the time of signing the form (ICF).
  • Diagnosed with moderate-to-severe chronic AD for at least 1 year before screening.
  • Eligible to be treated with dupilumab according to product monograph.
  • Pruritus lasting 6 or more weeks before baseline (Day 1).
  • Eczema Area and Severity Index (EASI) score >=12 at baseline.
  • Pruritus numerical rating scale (NRS) >=4 at baseline.
  • Investigator global assessment (IGA) score of >=3 at screening (on the 0 to 4 scale) at baseline.
  • Atopic dermatitis active lesions on the upper limbs or lower limbs suitable for a skin without oozing, bleeding, or infection on upper limbs or trunk.
  • Participants with acute AD lesions as determined by Investigator's judgment.
  • Stable treatment with non-prohibited medication or therapy during the study.

For Healthy participants

  • Male or female of >=18 years of age inclusive, at the time of signing the ICF.
  • Certified as generally healthy by a comprehensive clinical assessment.

Exclusion criteria

Exclusion criteria:

For AD participants

  • Previous treatment with dupilumab stopped within 6 months of baseline due to inadequate response to dupilumab.
  • Skin conditions other than AD that can confound assessments in the opinion of the investigator.
  • Regular use (>2 visits per week) of a tanning booth/parlor within 4 weeks of the Screening Visit.
  • Severe concomitant illness(es) that, in the Investigator's judgment, would adversely affect the participant's participation in the study.
  • Participants with active tuberculosis (TB) or non-TB mycobacterial infection, or a history of incompletely treated TB unless it is well documented the participant has been adequately treated and can now start treatment with a biologic agent
  • Diagnosed with, suspected of, or at high risk of endoparasitic infection, and/or use of antiparasitic drug within 2 weeks before the Screening Visit (Visit 1) or during the Screening Period.
  • Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, or antifungals within 2 weeks before the Screening Visit (Visit 1) or during the Screening Period.
  • Known or suspected immunodeficiency, including history of invasive opportunistic infections.
  • Active or history of malignancy within 5 years before the Baseline Visit, except completely treated in situ carcinoma of the cervix and completely treated and resolved non- squamous or basal cell carcinoma of the skin.
  • Ocular disorder that in the opinion of the Investigator could adversely affect the individual's risk for study participation. Examples include, but are not limited to, individuals with a history of active cases of herpes keratitis, Sjogren's syndrome, keratoconjunctivitis sicca or dry eye syndrome that require daily use of supplemental lubrication or individuals with ocular conditions that require the use of ocular or cyclosporine.
  • History of systemic or anaphylaxis to dupilumab or any other biologic therapy, including any .
  • Participant with any other medical or psychological condition including relevant laboratory or abnormalities at screening.

For healthy participants

  • Regular use (>2 visits per week) of a tanning booth/ parlor within 4 weeks of the Screening Visit.
  • Treatment with the following concomitant medications and procedures is prohibited within 4 weeks before the Screening Visit or 5 half-lives (whichever is longer) until End of Study Visit:

    • Topical medication
    • Analgesics
    • Immunomodulators
    • Antidepressants
    • Anti-anxiety drugs
  • Any Type 2 immune disorders uncontrolled Type 2 diabetes mellitus, Type 1 diabetes mellitus, neuropathy or any other neurological disease.
  • Any concomitant illness(es) or conditions that, in the Investigator's judgment, would adversely affect the participant's participation in the study or potentially affect any skin related read out.
  • Positive test for immunoglobulin E (IgE) antibodies.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • No intervention
    Healthy Participants: Control

    Healthy participants with site, age, gender, race, location of targeted lesional and non-lesional skin area matched to selected AD participants, received no treatment, and were considered as a control group.

  • Experimental
    Participants With AD: Dupilumab

    Participants with moderate to severe AD received dupilumab 600 milligrams (mg) subcutaneous (SC) injection on Day 1, followed by dupilumab 300 mg SC injection every 2 weeks (Q2W) from Week 3 to Week 15.

    Drug: Dupilumab (SAR231893)

Interventions

  • Pharmaceutical form: solution for injection Route of administration: subcutaneous

    Also known as: REGN668

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Intraepidermal Nerve Fiber Density on Lesional Skin at Week 17

    Skin biopsies were used to analyze the epidermal nerve fiber density. Nerve fibers were visualized by staining consecutive sections for the pan-axonal marker protein gene product 9.5 (PGP9.5); and the basement membrane was visualized by staining for collagen type 4. Quantification of intraepidermal nerve fiber density was calculated by assessing nerve fibers crossing the basement membrane per square millimeter (F/mm\^2). Data for this outcome measure was not planned to be collected and analyzed for "healthy participant" arm as pre-specified in protocol.

    Time frame: Baseline, Week 17

  2. Percentage of Participants With Change From Baseline in Nerve Fiber Branching on Lesional Skin at Week 17

    Skin biopsies were used to analyze the epidermal nerve fiber branching. Nerve fibers were visualized by staining consecutive sections for the pan-axonal marker PGP9.5; and the basement membrane was visualized by staining for collagen type 4. Branching of epidermal nerve fibers was assessed semi-quantitatively by classifying participants into 4 groups depending on the predominant intraepidermal nerve fiber branching pattern as follows: only linear (100% linear), mainly linear (\>60% linear), mainly branched (\>60% branched), only branched (100% branched). Percentage of participants with change in nerve fiber branching status from baseline on lesional skin at Week 17 are reported in this outcome measure.

    Time frame: Baseline, Week 17

Secondary outcomes

  1. Change From Baseline in Intraepidermal Nerve Fiber Density on Lesional Skin at Weeks 3 and 21

    Skin biopsies were used to analyze the epidermal nerve fiber density. Nerve fibers were visualized by staining consecutive sections for the pan-axonal marker PGP9.5; and the basement membrane was visualized by staining for collagen type 4. Quantification of intraepidermal nerve fiber density was calculated by assessing nerve fibers crossing the basement membrane per square millimeter (F/mm\^2).

    Time frame: Baseline, Weeks 3 and 21

  2. Change From Baseline in Nerve Fiber Branching on Lesional Skin at Weeks 3 and 21

    Skin biopsies were used to analyze the epidermal nerve fiber branching. Nerve fibers were visualized by staining consecutive sections for the pan-axonal marker PGP9.5; and the basement membrane was visualized by staining for collagen type 4. Branching of epidermal nerve fibers was assessed semi-quantitatively by classifying participants into 4 groups depending on the predominant intraepidermal nerve fiber branching pattern as follows: only linear (100% linear), mainly linear (\>60% linear), mainly branched (\>60% branched), only branched (100% branched).

    Time frame: Baseline, Weeks 3 and 21

  3. Change From Baseline in Peak Pruritus Assessed by Numeric Rating Scale (NRS) Scores at Weeks 17 and 21

    Peak Pruritus NRS was an assessment tool used to report the intensity of participant's pruritus (itch) during a daily recall period. Participants were asked to rate their worst itch on a 0 ("No itch") to 10 ("Worst itch imaginable") NRS by answering the following question: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". Higher scores indicated greater severity.

    Time frame: Baseline, Weeks 17 and 21

  4. Change From Baseline in Eczema and Severity Index (EASI) Total Score at Weeks 17 and 21

    EASI was a validated measure used to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, and edema\], scratching \[excoriation\], and lichenification) were each assessed for severity by the Investigator on a scale of "0" (absent) through "3" (severe). EASI area score was based upon percent (%) body surface area (BSA) with AD in each body region: 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), and 6 (90% to 100%). Total EASI score was derived as the sum of the 4 region scores and ranged from 0 (minimum) to 72 (maximum). Higher scores indicated greater severity of AD.

    Time frame: Baseline, Weeks 17 and 21

  5. Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Total Score at Weeks 17 and 21

    SCORAD was used to standardize the extent and severity of AD. It consisted of 3 components i.e., A =extent or affected BSA assessed as a % of each defined body area and reported as sum of all areas, with a maximum score of 100%. B=severity of 6 specific symptoms of AD (redness, swelling, oozing/crusting, excoriation, skin thickening/lichenification, dryness) assessed using following scale: none (0), mild (1), moderate (2), or severe (3) (for a maximum of 18 total points) and C=subjective symptoms scored by participants on VAS, where "0"=no itch (or no sleeplessness) and "10"=worst imaginable itch (or sleeplessness) with a maximum score of 20. SCORAD total score was calculated using these 3 aspects: extent (A: 0-100), severity (B: 0-18), and subjective symptoms (C: 0-20) using the formula: A/5 + 7\*B/2+ C. SCORAD total score ranged from 0 to 103, where 0 = no disease to 103 = severe disease. Higher values of SCORAD represent worse outcome.

    Time frame: Baseline, Weeks 17 and 21

  6. Change From Baseline in Patient-Reported Outcomes Measurement Information (PROMIS-itch) Itch-Severity Total Score at Weeks 17 and 21

    PROMIS-itch represents a novel suite of participant-reported outcome (PRO) measures for the itch. The PROMIS-Itch severity score consists of 7 questions: 4 questions scored on a scale of 1 to 5: 1) How intense was your itch at its worst; 2) How intense was your itch in general; 3) What is your level of itch right now; 4) How often did you feel the itch; and rest 3 questions (same questions as 1 to 3 mentioned before but scaled on a scale of 0 to 10) were scored on a scale of 0 to 10. Higher scores for each question indicated worse outcome. The total PROMIS-itch score was calculated as the sum of the 7 questions and ranged from 4 (better outcome) to 50 (worse outcome), where a higher score indicated worse condition.

    Time frame: Baseline, Weeks 17 and 21

  7. Change From Baseline in Patient Oriented Eczema Measure (POEM) Total Score at Weeks 17 and 21

    The POEM was a 7-item, validated questionnaire used in clinical practice and clinical trials to assess disease symptoms in children and adults with AD. The format is participant response to 7 items (dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping) based on symptom frequency during the past week (i.e., 0 = 'no days', 1 = '1 to 2 days', 2 = '3 to 4 days', 3 = '5 to 6' days, and 4 = 'every day'). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (severe disease). Higher scores indicated more severe disease and poor quality of life.

    Time frame: Baseline, Weeks 17 and 21

  8. Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Weeks 17 and 21

    DLQI was a 10-item PRO questionnaire that measured the impact of AD disease symptoms and treatment on quality of life. Each question was evaluated on a 4-point scale ranged from 0 to 3 where, 0 = not at all, 1= a little, 2= a lot, 3= very much, where higher scores indicated more impact on quality of life. Scores from all 10 questions were added up to give DLQI total score that ranged from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of participants.

    Time frame: Baseline, Weeks 17 and 21

  9. Change From Baseline in Atopic Dermatitis Control Tool (ADCT) Total Score at Weeks 17 and 21

    ADCT was a PRO questionnaire designed to assess participant-self-perceived control of their eczema. ADCT contained 6 items allowing a comprehensive coverage of the dimensions defining AD control, i.e., overall severity of AD symptoms, frequency of intense episodes of itching, extent of AD related bother, impact on sleep, impact on daily activities, impact on mood or emotions. Each item of the ADCT is rated from 0 (no problem) to 4 (worst) Likert scale and is equally weighted. The sum of the 6 items gives the total score that ranged from 0 (best disease control) to 24 (worst disease control). Higher scores indicate lower AD control.

    Time frame: Baseline, Weeks 17 and 21

  10. Change From Baseline in Sleep Quality Numerical Rating Scale Score at Weeks 17 and 21

    Sleep quality NRS was used to assess the quality of the participant's previous night's sleep using a 0 ("Worst possible sleep") to 10 ("Best possible sleep") NRS. Participants were asked to complete the following question upon awakening: "Select the number (0 to 10) that best describes the quality of your sleep last night". Higher score indicated better outcome.

    Time frame: Baseline, Weeks 17 and 21

  11. Change From Baseline in Skin Pain Numerical Rating Scale Score at Weeks 17 and 21

    Skin pain NRS was used to assess participant's skin pain at its worst in the past 24 hours using a 0 ("Not at all") to 10 ("Very much") NRS. Participants were asked the following question: "Think about all the areas of your skin with eczema. How much did your skin burn at its worst in the past 24 hours?" Lower score indicated better outcome.

    Time frame: Baseline, Weeks 17 and 21

  12. Change From Baseline in Skin Sensitivity Numerical Rating Scale Score at Weeks 17 and 21

    Skin sensitivity NRS was a 1 item PRO measure asking the participants to rate their skin sensitivity to touch using a 0 ("Normal") to 10 ("Extremely sensitive") NRS. Participants were asked the following question: "Think about all the areas of your skin with eczema. How sensitive was your skin at its worst in the past 24 hours?" Lower score indicated better outcome.

    Time frame: Baseline, Weeks 17 and 21

  13. Change From Baseline in Skin Burning Numerical Rating Scale Score at Weeks 17 and 21

    Skin burning NRS was a 1-item PRO measure asking participants to rate the burning sensation of their skin in the past 24 hours using a 0 ("Not at all") to 10 ("Very much") NRS. Participants were asked the following question: "Think about all the areas of your skin with eczema. How much did your skin burn at its worst in the past 24 hours?" Lower score indicated better outcome.

    Time frame: Baseline, Weeks 17 and 21

  14. Percentage of Participants With Change of Greater Than or Equal to (>=4) Point in Pruritus Numerical Rating Scale From Baseline at Weeks 17 and 21

    Pruritus NRS was an assessment tool used to report the intensity of participant's pruritus (itch) during a daily recall period. Participants were asked to rate their worst itch on a 0 ("No itch") to 10 ("Worst itch imaginable") NRS by answering the following question: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". Higher scores indicated greater severity. Percentage of participants with change of \>=4 point in pruritus NRS scale from baseline at Weeks 17 and 21 are reported in this outcome measure.

    Time frame: Baseline, Weeks 17 and 21

07

Results

Posted Jul 11, 2023

Participant flow

The study was conducted at 3 active sites in the United States and Germany. A total of 54 participants were enrolled between 22 April 2021 to 30 March 2022.

Participant flow — Overall Study
MilestoneHealthy Participants: ControlParticipants With AD: Dupilumab
Started1935
Safety population1331
Completed1028
Not completed97
Withdrew: Withdrawal by subject23
Withdrew: Failure to meet inclusion criteria64
Withdrew: Other-unspecified10

Outcome measures

PrimaryChange From Baseline in Intraepidermal Nerve Fiber Density on Lesional Skin at Week 17

Skin biopsies were used to analyze the epidermal nerve fiber density. Nerve fibers were visualized by staining consecutive sections for the pan-axonal marker protein gene product 9.5 (PGP9.5); and the basement membrane was visualized by staining for collagen type 4. Quantification of intraepidermal nerve fiber density was calculated by assessing nerve fibers crossing the basement membrane per square millimeter (F/mm\^2). Data for this outcome measure was not planned to be collected and analyzed for "healthy participant" arm as pre-specified in protocol.

Time frame:
Baseline, Week 17
Reported as:
Mean · F/mm^2
Change From Baseline in Intraepidermal Nerve Fiber Density on Lesional Skin at Week 17
F/mm^2Participants With AD: Dupilumab
Baseline8.4567 ± 7.2502
Change at Week 174.2618 ± 6.7538
PrimaryPercentage of Participants With Change From Baseline in Nerve Fiber Branching on Lesional Skin at Week 17

Skin biopsies were used to analyze the epidermal nerve fiber branching. Nerve fibers were visualized by staining consecutive sections for the pan-axonal marker PGP9.5; and the basement membrane was visualized by staining for collagen type 4. Branching of epidermal nerve fibers was assessed semi-quantitatively by classifying participants into 4 groups depending on the predominant intraepidermal nerve fiber branching pattern as follows: only linear (100% linear), mainly linear (\>60% linear), mainly branched (\>60% branched), only branched (100% branched). Percentage of participants with change in nerve fiber branching status from baseline on lesional skin at Week 17 are reported in this outcome measure.

Time frame:
Baseline, Week 17
Reported as:
Number · percentage of participants
Percentage of Participants With Change From Baseline in Nerve Fiber Branching on Lesional Skin at Week 17
percentage of participantsParticipants With AD: Dupilumab
Only linear0
Mainly linear60.0
Mainly branched40.0
Only branched0
SecondaryChange From Baseline in Intraepidermal Nerve Fiber Density on Lesional Skin at Weeks 3 and 21

Skin biopsies were used to analyze the epidermal nerve fiber density. Nerve fibers were visualized by staining consecutive sections for the pan-axonal marker PGP9.5; and the basement membrane was visualized by staining for collagen type 4. Quantification of intraepidermal nerve fiber density was calculated by assessing nerve fibers crossing the basement membrane per square millimeter (F/mm\^2).

Time frame:
Baseline, Weeks 3 and 21

No measurements were reported for this outcome.

SecondaryChange From Baseline in Nerve Fiber Branching on Lesional Skin at Weeks 3 and 21

Skin biopsies were used to analyze the epidermal nerve fiber branching. Nerve fibers were visualized by staining consecutive sections for the pan-axonal marker PGP9.5; and the basement membrane was visualized by staining for collagen type 4. Branching of epidermal nerve fibers was assessed semi-quantitatively by classifying participants into 4 groups depending on the predominant intraepidermal nerve fiber branching pattern as follows: only linear (100% linear), mainly linear (\>60% linear), mainly branched (\>60% branched), only branched (100% branched).

Time frame:
Baseline, Weeks 3 and 21

No measurements were reported for this outcome.

SecondaryChange From Baseline in Peak Pruritus Assessed by Numeric Rating Scale (NRS) Scores at Weeks 17 and 21

Peak Pruritus NRS was an assessment tool used to report the intensity of participant's pruritus (itch) during a daily recall period. Participants were asked to rate their worst itch on a 0 ("No itch") to 10 ("Worst itch imaginable") NRS by answering the following question: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". Higher scores indicated greater severity.

Time frame:
Baseline, Weeks 17 and 21
Reported as:
Mean · score on a scale
Change From Baseline in Peak Pruritus Assessed by Numeric Rating Scale (NRS) Scores at Weeks 17 and 21
score on a scaleParticipants With AD: Dupilumab
Week 17-6.6 ± 3.6
Week 21-7.4 ± 1.4
SecondaryChange From Baseline in Eczema and Severity Index (EASI) Total Score at Weeks 17 and 21

EASI was a validated measure used to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, and edema\], scratching \[excoriation\], and lichenification) were each assessed for severity by the Investigator on a scale of "0" (absent) through "3" (severe). EASI area score was based upon percent (%) body surface area (BSA) with AD in each body region: 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), and 6 (90% to 100%). Total EASI score was derived as the sum of the 4 region scores and ranged from 0 (minimum) to 72 (maximum). Higher scores indicated greater severity of AD.

Time frame:
Baseline, Weeks 17 and 21
Reported as:
Mean · score on a scale
Change From Baseline in Eczema and Severity Index (EASI) Total Score at Weeks 17 and 21
score on a scaleParticipants With AD: Dupilumab
Week 17-18.9 ± 6.4
Week 21-19.5 ± 6.4
SecondaryChange From Baseline in Scoring Atopic Dermatitis (SCORAD) Total Score at Weeks 17 and 21

SCORAD was used to standardize the extent and severity of AD. It consisted of 3 components i.e., A =extent or affected BSA assessed as a % of each defined body area and reported as sum of all areas, with a maximum score of 100%. B=severity of 6 specific symptoms of AD (redness, swelling, oozing/crusting, excoriation, skin thickening/lichenification, dryness) assessed using following scale: none (0), mild (1), moderate (2), or severe (3) (for a maximum of 18 total points) and C=subjective symptoms scored by participants on VAS, where "0"=no itch (or no sleeplessness) and "10"=worst imaginable itch (or sleeplessness) with a maximum score of 20. SCORAD total score was calculated using these 3 aspects: extent (A: 0-100), severity (B: 0-18), and subjective symptoms (C: 0-20) using the formula: A/5 + 7\*B/2+ C. SCORAD total score ranged from 0 to 103, where 0 = no disease to 103 = severe disease. Higher values of SCORAD represent worse outcome.

Time frame:
Baseline, Weeks 17 and 21
Reported as:
Mean · score on a scale
Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Total Score at Weeks 17 and 21
score on a scaleParticipants With AD: Dupilumab
Week 17-77.2 ± 32.3
Week 21-81.3 ± 35.0
SecondaryChange From Baseline in Patient-Reported Outcomes Measurement Information (PROMIS-itch) Itch-Severity Total Score at Weeks 17 and 21

PROMIS-itch represents a novel suite of participant-reported outcome (PRO) measures for the itch. The PROMIS-Itch severity score consists of 7 questions: 4 questions scored on a scale of 1 to 5: 1) How intense was your itch at its worst; 2) How intense was your itch in general; 3) What is your level of itch right now; 4) How often did you feel the itch; and rest 3 questions (same questions as 1 to 3 mentioned before but scaled on a scale of 0 to 10) were scored on a scale of 0 to 10. Higher scores for each question indicated worse outcome. The total PROMIS-itch score was calculated as the sum of the 7 questions and ranged from 4 (better outcome) to 50 (worse outcome), where a higher score indicated worse condition.

Time frame:
Baseline, Weeks 17 and 21
Reported as:
Mean · score on a scale
Change From Baseline in Patient-Reported Outcomes Measurement Information (PROMIS-itch) Itch-Severity Total Score at Weeks 17 and 21
score on a scaleParticipants With AD: Dupilumab
Week 17-30.8 ± 9.0
Week 21-28.8 ± 11.5
SecondaryChange From Baseline in Patient Oriented Eczema Measure (POEM) Total Score at Weeks 17 and 21

The POEM was a 7-item, validated questionnaire used in clinical practice and clinical trials to assess disease symptoms in children and adults with AD. The format is participant response to 7 items (dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping) based on symptom frequency during the past week (i.e., 0 = 'no days', 1 = '1 to 2 days', 2 = '3 to 4 days', 3 = '5 to 6' days, and 4 = 'every day'). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (severe disease). Higher scores indicated more severe disease and poor quality of life.

Time frame:
Baseline, Weeks 17 and 21
Reported as:
Mean · score on a scale
Change From Baseline in Patient Oriented Eczema Measure (POEM) Total Score at Weeks 17 and 21
score on a scaleParticipants With AD: Dupilumab
Week 17-17.2 ± 5.3
Week 21-16.1 ± 5.9
SecondaryChange From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Weeks 17 and 21

DLQI was a 10-item PRO questionnaire that measured the impact of AD disease symptoms and treatment on quality of life. Each question was evaluated on a 4-point scale ranged from 0 to 3 where, 0 = not at all, 1= a little, 2= a lot, 3= very much, where higher scores indicated more impact on quality of life. Scores from all 10 questions were added up to give DLQI total score that ranged from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of participants.

Time frame:
Baseline, Weeks 17 and 21
Reported as:
Mean · score on a scale
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Weeks 17 and 21
score on a scaleParticipants With AD: Dupilumab
Week 17-16.1 ± 7.4
Week 21-14.8 ± 8.1
SecondaryChange From Baseline in Atopic Dermatitis Control Tool (ADCT) Total Score at Weeks 17 and 21

ADCT was a PRO questionnaire designed to assess participant-self-perceived control of their eczema. ADCT contained 6 items allowing a comprehensive coverage of the dimensions defining AD control, i.e., overall severity of AD symptoms, frequency of intense episodes of itching, extent of AD related bother, impact on sleep, impact on daily activities, impact on mood or emotions. Each item of the ADCT is rated from 0 (no problem) to 4 (worst) Likert scale and is equally weighted. The sum of the 6 items gives the total score that ranged from 0 (best disease control) to 24 (worst disease control). Higher scores indicate lower AD control.

Time frame:
Baseline, Weeks 17 and 21
Reported as:
Mean · score on a scale
Change From Baseline in Atopic Dermatitis Control Tool (ADCT) Total Score at Weeks 17 and 21
score on a scaleParticipants With AD: Dupilumab
Week 17-17.9 ± 4.1
Week 21-15.9 ± 6.2
SecondaryChange From Baseline in Sleep Quality Numerical Rating Scale Score at Weeks 17 and 21

Sleep quality NRS was used to assess the quality of the participant's previous night's sleep using a 0 ("Worst possible sleep") to 10 ("Best possible sleep") NRS. Participants were asked to complete the following question upon awakening: "Select the number (0 to 10) that best describes the quality of your sleep last night". Higher score indicated better outcome.

Time frame:
Baseline, Weeks 17 and 21
Reported as:
Mean · score on a scale
Change From Baseline in Sleep Quality Numerical Rating Scale Score at Weeks 17 and 21
score on a scaleParticipants With AD: Dupilumab
Week 170.7 ± 5.0
Week 213.0 ± 5.4
SecondaryChange From Baseline in Skin Pain Numerical Rating Scale Score at Weeks 17 and 21

Skin pain NRS was used to assess participant's skin pain at its worst in the past 24 hours using a 0 ("Not at all") to 10 ("Very much") NRS. Participants were asked the following question: "Think about all the areas of your skin with eczema. How much did your skin burn at its worst in the past 24 hours?" Lower score indicated better outcome.

Time frame:
Baseline, Weeks 17 and 21
Reported as:
Mean · score on a scale
Change From Baseline in Skin Pain Numerical Rating Scale Score at Weeks 17 and 21
score on a scaleParticipants With AD: Dupilumab
Week 17-5.3 ± 2.9
Week 21-5.3 ± 2.2
SecondaryChange From Baseline in Skin Sensitivity Numerical Rating Scale Score at Weeks 17 and 21

Skin sensitivity NRS was a 1 item PRO measure asking the participants to rate their skin sensitivity to touch using a 0 ("Normal") to 10 ("Extremely sensitive") NRS. Participants were asked the following question: "Think about all the areas of your skin with eczema. How sensitive was your skin at its worst in the past 24 hours?" Lower score indicated better outcome.

Time frame:
Baseline, Weeks 17 and 21
Reported as:
Mean · score on a scale
Change From Baseline in Skin Sensitivity Numerical Rating Scale Score at Weeks 17 and 21
score on a scaleParticipants With AD: Dupilumab
Week 17-7.7 ± 1.5
Week 21-7.3 ± 2.2
SecondaryChange From Baseline in Skin Burning Numerical Rating Scale Score at Weeks 17 and 21

Skin burning NRS was a 1-item PRO measure asking participants to rate the burning sensation of their skin in the past 24 hours using a 0 ("Not at all") to 10 ("Very much") NRS. Participants were asked the following question: "Think about all the areas of your skin with eczema. How much did your skin burn at its worst in the past 24 hours?" Lower score indicated better outcome.

Time frame:
Baseline, Weeks 17 and 21
Reported as:
Mean · score on a scale
Change From Baseline in Skin Burning Numerical Rating Scale Score at Weeks 17 and 21
score on a scaleParticipants With AD: Dupilumab
Week 17-4.3 ± 1.5
Week 21-5.5 ± 2.9
SecondaryPercentage of Participants With Change of Greater Than or Equal to (>=4) Point in Pruritus Numerical Rating Scale From Baseline at Weeks 17 and 21

Pruritus NRS was an assessment tool used to report the intensity of participant's pruritus (itch) during a daily recall period. Participants were asked to rate their worst itch on a 0 ("No itch") to 10 ("Worst itch imaginable") NRS by answering the following question: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". Higher scores indicated greater severity. Percentage of participants with change of \>=4 point in pruritus NRS scale from baseline at Weeks 17 and 21 are reported in this outcome measure.

Time frame:
Baseline, Weeks 17 and 21
Reported as:
Number · percentage of participants
Percentage of Participants With Change of Greater Than or Equal to (>=4) Point in Pruritus Numerical Rating Scale From Baseline at Weeks 17 and 21
percentage of participantsParticipants With AD: Dupilumab
Week 170
Week 210

Adverse events

Collected over For Dupilumab group participants: from first dose (i.e., Day 1) of IMP administration up to end of study visit (i.e., up to Week 21). For healthy participants: from Baseline up to end of study for healthy participants group (i.e., at Day 8). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Healthy Participants: Control0/13 (0%)0/13 (0%)0/13 (0%)
Participants With AD: Dupilumab0/31 (0%)1/31 (3.2%)24/31 (77.4%)
Most frequent serious events
Most frequent serious events
EventHealthy Participants: ControlParticipants With AD: Dupilumab
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders0/131/31
Most frequent other events
Showing 10 of 35
Most frequent other events
EventHealthy Participants: ControlParticipants With AD: Dupilumab
HeadacheNervous system disorders0/137/31
Dermatitis AtopicSkin and subcutaneous tissue disorders0/133/31
ConjunctivitisInfections and infestations0/132/31
Eye PruritusEye disorders0/132/31
NauseaGastrointestinal disorders0/132/31
Asymptomatic Covid-19Infections and infestations0/131/31
BronchitisInfections and infestations0/131/31
CystitisInfections and infestations0/131/31
ImpetigoInfections and infestations0/131/31
NasopharyngitisInfections and infestations0/131/31

Baseline characteristics

Analysis was performed on enrolled population.

Age, Continuous
Age, Continuous(years)Healthy Participants: ControlParticipants With AD: DupilumabTotal
Mean41.3 ± 14.141.2 ± 18.141.2 ± 16.7
Sex: Female, Male
Sex: Female, Male(Participants)Healthy Participants: ControlParticipants With AD: DupilumabTotal
Female131932
Male61622
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Healthy Participants: ControlParticipants With AD: DupilumabTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American000
White193352
More than one race011
Unknown or Not Reported000
08

Study locations

3 sites
  • Investigational Site Number 8400001
    Miami, Florida 33136, United States
  • Investigational Site Number 8400002
    East Windsor, New Jersey 08520, United States
  • Investigational Site Number 2760001
    Münster, 48149, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Jun 2022, 14 months.

Results were first posted in Jul 2023, 1 year after primary completion.

Of 45 phase 4 interventional studies under Dermatitis, Atopic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2021
First posted
Mar 30, 2021
StartActual
Apr 22, 2021
Primary completionActual
Jun 30, 2022
CompletionActual
Aug 30, 2022
Results first posted
Jul 11, 2023
Last update
Sep 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04823130
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Mar 30, 2021
Start date
Apr 22, 2021
Primary completion
Jun 30, 2022
Completion
Aug 30, 2022
Results posted
Jul 11, 2023
Last update
Sep 16, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion